(NASDAQ:VXRT),(OTC US:VXRT),(Other OTC:VXRT), Reported positive topline data from Phase 1 clinical trial evaluating Company's second-generation oral norovirus vaccine constructs, supporting potential for improved protection against infection Enrolled approximately 5,000 participants in COVID-19 Phase 2b trial prior to stop work order; Follow-up for all participants dosed, including 400-person sentinel cohort continues Cash, cash equivalents and investments […]

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire August 13, 2025 -Completed enrollment in Phase 3 ONWARD clinical trials for envudeucitinib in moderate-to-severe plaque psoriasis; topline readout expected in early Q1 2026- -Completed enrollment in Phase 2b LUMUS clinical trial for envudeucitinib in systemic lupus erythematosus (SLE); topline readout expected in

Global Crossing Airlines Reports Second Quarter 2025 Financial Results GlobeNewswire August 13, 2025 GAAP Net Income of $0.6 Million or $0.01 per Share; EBITDAR1 of $19.8 Million Generated Record Block Hours of 8,065 in Q2 MIAMI, Aug. 13, 2025 (GLOBE NEWSWIRE) — Global Crossing Airlines Group, Inc. (Cboe CA: JET, Cboe CA: JET.B, OTCQB: JETMF)

Hyperfine, Inc. Reports Second Quarter 2025 Financial Results GlobeNewswire August 13, 2025 GUILFORD, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) — Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system–the Swoop(R) system–today announced second quarter 2025 financial results and

STRATA Skin Sciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update GlobeNewswire August 13, 2025 HORSHAM, Penn., Aug. 13, 2025 (GLOBE NEWSWIRE) — STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces

Barfresh Announces Second Quarter 2025 Results GlobeNewswire August 13, 2025 Revenue Increased 11% Year-Over-Year to $1.6 Million for Second Quarter 2025 Achieved Gross Margin of 31% for Second Quarter 2025 New Co-Manufacturer Completes Equipment Installation at End of Second Quarter 2025 and Commences Increased Supply for Third Quarter 2025 Company Expects an Increase in Revenue

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update GlobeNewswire August 13, 2025 KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced its second quarter financial results and provided a business update. Highlights of

The Oncology Institute Reports Second Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance GlobeNewswire August 13, 2025 CERRITOS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) — The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its

Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire August 13, 2025 Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 CHAPEL HILL, N.C., Aug.

Coherent Corp. Reports Fourth Quarter and Full Year Fiscal 2025 Results GlobeNewswire August 13, 2025 FY25 REVENUE OF $5.81B, INCREASED 23% Y/Y FY25 GAAP GROSS MARGIN OF 35.2%, INCREASED 424 bps Y/Y; FY25 NON-GAAP GROSS MARGIN OF 37.9%, INCREASED 358 bps Y/Y FY25 GAAP LOSS OF $0.52, IMPROVED $1.32 Y/Y; FY25 NON-GAAP EPS OF $3.53,